MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Chorea improvements over time with once-daily valbenazine treatment in adults with Huntington disease

    E. Furr Stimming, E. Kayson, J. Goldstein, H. Zhang, O. Klepitskaya, G. Liang, D. Haubenberger (Houston, USA)

    Objective: To describe the effects of valbenazine (VBZ) over time on chorea in adults with Huntington disease (HD). Background: The Ph3 KINECTTM-HD (NCT04102579) trial met…
  • 2023 International Congress

    First case of sporadic ATP6AP2 Mutation reported in Asia in a Parkinson’s Disease patient

    K. Shukla, N. Sawal (Chandigarh, India)

    Objective: Genetic analysis of Parkinson's Disease (PD) with features of spasticity by Whole Exome Sequencing (WES) and use of its result for treatment modification to…
  • 2023 International Congress

    Subthalamic Nucleus Deep Brain Stimulation in GBA-associated Parkinson Disease: Cognitive and motor follow-up of two clinical cases

    I. Carvalho, D. Damas, I. Cunha, S. Caldeira, P. Monteiro, R. Pereira, F. Moreira (Coimbra, Portugal)

    Objective: To report the long-term motor and cognitive outcome of two patients with GBA-associated Parkinson’s disease (PD) who underwent STN-DBS surgery. Background: Recent studies suggest…
  • 2023 International Congress

    Generalized chorea, cerebellar ataxia and spastic tetraparesis with a genetic mutation in FAT2 gene – coincidence or a new SCA45 phenotype?

    M. Sequeira, D. Melancia (Lisboa, Portugal)

    Objective: To present what might be a new phenotype of spinocerebellar ataxia type 45. Background: Spinocerebellar ataxias (SCAs) are a heterogeneous group of autosomal dominant,…
  • 2023 International Congress

    Impact of the COVID-19 pandemic in the long-term efficacy of botulinum toxin treatment

    F. Barros, C. Nunes, F. Magalhães, A. Mestre, C. Machado, D. Carneiro (Coimbra, Portugal)

    Objective: To analyse the impact of the COVID-19 pandemic in the long-term efficacy of treatment with botulinum toxin (BoT). Background: The COVID-19 pandemic brought new…
  • 2023 International Congress

    Double-blind, randomized, crossover clinical trial to compare VIM vs PSA deep brain stimulation in patients with disabling essential tremor. Preliminary results.

    L. Triguero-Cueva, CJ. Madrid Navarro, MJ. Perez Navarro, B. Iáñez Velasco, M. Jouma Katati, JP. Martínez Barbero, A. Mínguez-Castellanos, F. Escamilla Sevilla (Jódar, Spain)

    Objective: To compare the safety, efficacy, energy efficiency and quality of life (QoL) outcomes of bilateral PSA-DBS vs bilateral VIM-DBS in the treatment of refractory…
  • 2023 International Congress

    Huntington’s disease patients with intermediate allele in Tunisia

    H. Nehdi, Z. Saied, F. Nabli, S. Ben Sassi, R. Amouri (Tunis, Tunisia)

    Objective: To explore the clinical and molecular findings of two Tunisian patients with LOHD and carriers of an IA. Background: Huntington's disease (HD) is an autosomal…
  • 2023 International Congress

    Prodromal stage early biomarkers in Parkinson’s disease and parkinsonism in Uzbek nationality

    DT. Akramova, GS. Rakhimbaeva (Tashkent, Uzbekistan)

    Objective: Evaluation of prodromal stage biomarkers in Parkinson's disease and their role in disease progression Background: From a pathophysiological point of view, PD is characterized…
  • 2023 International Congress

    The prevalence and clinical features of GBA-related Parkinson’s disease in a Slovak patient cohort

    A. Lackova, J. Necpal, V. Han, P. Pavelekova, K. Kulcsarova, T. Svorenova, L. Baranova, E. Tusay, B. Kovacova, E. Petro, B. Stasko, K. Burasova, M. Ostrozovicova, S. Bohacova, Z. Gdovinova, M. Skorvanek (Kosice, Slovakia)

    Objective: The aim of our study was to determine the prevalence and clinical characteristics of Slovak GBA-related patients with Parkinson's disease (PwP). Background: GBA variants…
  • 2023 International Congress

    parkinson’s disease and coffee: is high consumption a protective factor or aversion to coffee taste a risk factor?

    G. Procópio, C. Lobo, H. Dourado, MA. Silveira, AE. Lima, I. Oliveira, L. de Almeida, G. Valença (Salvador, Brazil)

    Objective: To evaluate the association between coffee consumption and preference for the taste of coffee with Parkinson's Disease (PD). Background: Previous studies point to a…
  • « Previous Page
  • 1
  • …
  • 619
  • 620
  • 621
  • 622
  • 623
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley